MD Biosciences Blog

Pain Response in Pigs Mimics Human Pain Behavior

Posted by MD Biosciences on Nov 17, 2015 12:10:56 PM

The pig peripheral neuritis trauma (PNT) model is an important transitional model that bridges the gap between animal research and the clinic. While we discussed how the the pig PNT model shares many morphological and molecular pathology similarities with skin biopsies from human pain conditions in our poster pdf, our chief scientist was the last, principle author in a preceding publication entitled “Peripheral Neuritis Trauma In Pigs: A Neuropathic Pain Model” in the Journal of Pain. In this paper, authors examine this model in terms of how it relates to the human pain response.

Read More

Topics: Pain, Neuro/CNS, Stress, neuropathic pain

Biomarkers Put Precision In Precision Medicine | AMP 2015

Posted by MD Biosciences on Nov 12, 2015 12:58:51 PM

The 2015 annual AMP meeting opened Novemeber 5th in Austin TX, with a presentation by Dr Brian Druker titled “Imatinib as a Paradigm of Targeted Cancer Therapies.”  This year’s recipient of the AMP Award for Excellence in Molecular Diagnostics, Dr Druker highlighted the importance of identifying patients through biomarkers and matching therapies to the patient.  This theme continued through many of the presentations, posters and vendor exhibits the importance of providing physicians actionable results for patient care and therapeutics.  Molecular diagnostics are critical to any discussion on precision or personalized medicine. 

Read More

Topics: cancer/tumor, Microbiome, Biomarkers, Association for Molecular Pathology, Pathology, precision medicine

Join MD Biosciences for AMP 2015 Annual Meeting

Posted by MD Biosciences on Nov 2, 2015 2:30:00 PM

MD Biosciences will be attending the Association for Molecular Pathology 2015 Conference in Austen Texas on November 5-7. The conference will focus on “realizing the dream of precision medicine”. As a CLIA lab, we are looking forward to meeting with our colleagues in the diagnostic industry and discussing the latest updates in testing and treatments in cancer and infectious diseases. Additionally, we are excited to hear about the cutting edge research occurring in clinical translational medicine and pharmacogenomics. Please contact us at [email protected] if you would like to meet at the conference. Stay tuned for our blog recap of the event.

Read More

Topics: AMP, Association for Molecular Pathology, Pathology, CLIA

Pig Model Validation In Neuropathic Pain-SfN 2015

Posted by MD Biosciences on Oct 30, 2015 3:31:09 PM

Last week, MD Biosciences presented a poster at the Society for Neurosciences 2015 Conference in Chicago. As strong advocates for the use of pig in translational neuropathic pain research, we introduced a new pig proximal peripheral neuritis trauma (PNT) model that shares many similarities in morphological and molecular pathologies with skin biopsies from human pain conditions. This is particularly true in comparisons with patients suffering from persistent area pain conditions such as postherpetic neuralgia (PHN) and complex regional pain syndrome (CRPS) as well as other chronic pain conditions.

Read More

Topics: Pain, Neuro/CNS, Stress, trauma pain, pain biomarkers, CNS imaging, Imaging

Stress, Trauma & Pain- Image Not Imagine The Evidence| Biomarkers

Posted by MD Biosciences on Sep 11, 2015 10:00:00 AM

 The 9th Annual Congress of the European Pain Federation EFIC® was anything but painful as it concluded last week in Vienna with three days of riveting talks. The speakers consisted of expert pain practitioners, scientists, and policy makers who came together with the goal of “translating evidence into practice”.

Read More

Topics: Pain, Neuro/CNS, EFIC 2015, Stress, Imaging, European Pain Federation

Targeting Microbiomes & Biomarkers: Inflammation World Congress

Posted by MD Biosciences on Aug 20, 2015 3:30:00 PM


The 12th World Congress on Inflammation wrapped up on Wednesday August 12th after four days packed with cutting edge inflammatory research by key opinions leaders in the field. Presentations hit every aspect of the scientific spectrum from development of pre-clinical models through retrospective studies on new target therapies and everything in between. Highlights of the conference included the Keynote Lecture by Luke O’Neill of Trinity College Dublin, the Symposium “Mechanisms Underlying Microbiome-Mediated Inflammation”, and multiple discussions on identifying and targeting novel biomarkers of inflammatory diseases.

Read More

Topics: Inflammation, metabolic, Preclinical Discovery, Microbiome, Biomarkers, World Congress on Inflammation

The Pathology of the IL-33/T1/ST2 Pathway: Harmin’ Alarmin

Posted by MD Biosciences on Aug 10, 2015 4:30:00 PM

IL-33 is a member of the IL-1 cytokine family that is expressed constitutively in the nucleus of epithelial and endothelial cells as well as in CNS oligodendrocyte and astrocyte cells (1-2). Its release in response to cell damage and/or death has earned it the classification of “alarmin” – an immunological alarm signal that is released in times of cellular distress (3-4). Upon release, IL-33 binds to the T1/ST2 and IL-1R accessory protein (IL-1RAP) heterodimer complex to activate the MYD88-dependant signaling pathway (1).

Studies targeting the function of IL-33 and/or signaling through its T1/ST2 receptor have highlighted the dual role this versatile cytokine pathway plays in the induction inflammatory immune reactions. More interestingly, these reactions can be either beneficial or pathological in nature. Here we will discuss the pathological role of IL-33 in disease.

Read More

Topics: Dermal, Inflammation, Research Products, Infection, Acute Kidney Injury (AKI)

Successfully Predict Neuropathic Pain Conditions

Posted by MD Biosciences on Jun 29, 2015 11:21:00 AM

The rodent has historically been used as the dominant model for the study of pain mechanisms and new therapeutics. There are good reasons for this such as the practicalities and ease of use with small animals as well as the scientific value of having a large database of prior research for predictive validity. The rodent models will continue to be the workhorse driving research and drug discovery, however there is a large failure rate of drugs moving into clinical stages, which failure of rodent models to predict the biology of the clinical condition certainly plays a role. The most well known example of this is the NK1 antagonist that exhibited efficacy-related translational failure in the clinic.

Read More

Topics: Neuro/CNS

Novel Biomarkers| Detecting early-stage Acute Kidney Injury (AKI)

Posted by MD Biosciences on May 7, 2015 10:47:16 AM

Acute kidney injury is a disease that is characterized by a rapid loss of kidney function, including the rapid fall in glomerular filtration rate (GFR) and the retention of nitrogenous waste over the course of hours and days. AKI is a complex, multifactorial disease with inflammatory, ischemic, necrotic and apoptotic events that occur simultaneously, leading to damage and functional kidney failure. The process of kidney injury occurs in stages starting with increased risk, followed by damage as a result of ischemic injury or toxicity, followed by a decrease in glomerular filtration rate (GFR), which further progresses to kidney failure.

Read More

Topics: Acute Kidney Injury (AKI)

Drug Discovery Success Rates | Role of Preclinical Study Design.

Posted by MD Biosciences on Apr 22, 2015 12:16:55 AM

In 2014, an article was published in Nature analyzing the clinical development success rates for investigational drugs. It's no surprise that the success rates are still somewhat dismal with 1 in 10 drugs that enter clinical phases pushing through to FDA approval. The article breaks down the success rate in each phase for differing classes of drugs as well as various therapeutic indications. NMEs were found to have the lowest success rates in every phase of development (7.5%) whereas biologics had nearly two times the success rate (14.6%).

Read More

Topics: Preclinical Discovery